ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

LG Chem and Innovent Biologics side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

LG ChemInnovent Biologics
studies on the registry184218
open to participants now1059
phase 3 studies under way323
reach primary completion within a year236
programswith a study of their own in two years1040

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseLG ChemInnovent Biologics
Phase 1

LG Chem: 2 of its 10 programs at phase 1

  1. Reference Drug (Eutropin, 4 IU/vial)phase 1
  2. Test Drug (Eutropin Catridge, 48IU/Cartridge)phase 1
20%

Innovent Biologics: 14 of its 40 programs at phase 1

  1. IBI3033phase 1
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. Anti-CEACAM5 Antibody-drug Conjugate IBI3020phase 1
  5. IBI115phase 1

and 9 more — sign in to see them all

35%
Phase 2

LG Chem: 1 of its 10 programs at phase 2

  1. LG00313112phase 2
10%

Innovent Biologics: 10 of its 40 programs at phase 2

  1. IBI3016phase 2
  2. telitaciceptphase 2
  3. IBI355phase 2
  4. IBI3002phase 2
  5. IBI3011phase 2

and 5 more — sign in to see them all

25%
Phase 3

LG Chem: 4 of its 10 programs at phase 3

  1. rilogrotugphase 3
  2. LBVDphase 3
  3. Metforminphase 3
  4. dapagliflozinphase 3
40%
38%
Approved, new studies

LG Chem: 3 of its 10 programs at approved, new studies

  1. Fang Le Shu (Follitrope)approved, new study
  2. Leuprolideapproved, new study
  3. gemigliptinapproved, new study
30%

Innovent Biologics: 1 of its 40 programs at approved, new studies

  1. Teprotumumab N01approved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
LG Chem0 readouts · 0 phase 3············
Innovent Biologics18 readouts · 4 phase 3

Innovent Biologics, Nov ’26: 1 program whose next study reaches primary completion

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3 · Nov 30 · NCT07122687

Innovent Biologics, Dec ’26: 6 programs whose next study reaches primary completion, 3 in phase 3

  1. arcotatug tavatecanphase 3 · Dec 30 · NCT06238843
  2. GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003phase 3 · Dec 31 · NCT07764861
  3. IBI302phase 3 · Dec 31 · NCT06908876
  4. IBI3026early phase 1 · Dec 31 · NCT07327632
  5. IBI311phase 3 · Dec 31 · NCT07113262

and 1 more — sign in to see them all

Innovent Biologics, Jan ’27: 3 programs whose next study reaches primary completion

  1. IBI3016phase 2 · Jan 30 · NCT07838220
  2. IBI3034phase 1 · Jan 31 · NCT07886476
  3. telitaciceptphase 2 · Jan 31 · NCT07886476

Innovent Biologics, Feb ’27: 2 programs whose next study reaches primary completion

  1. IBI3042phase 1 · Feb 3 · NCT07842393
  2. IBI3033phase 1 · Feb 10 · NCT07549984

Innovent Biologics, Mar ’27: 1 program whose next study reaches primary completion

  1. IBI3002phase 2 · Mar 23 · NCT07399067

Innovent Biologics, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tigulixostatphase 3 · Apr 30 · NCT07414394

Innovent Biologics, May ’27: 1 program whose next study reaches primary completion

  1. IBI3011phase 2 · May 11 · NCT07842497

Innovent Biologics, Jun ’27: 2 programs whose next study reaches primary completion

  1. IBI3031phase 1 · Jun 15 · NCT07622368
  2. IBI3028phase 1 · Jun 30 · NCT07589205

Innovent Biologics, Jul ’27: 1 program whose next study reaches primary completion

  1. IBI3035phase 1 · Jul 30 · NCT07591519
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

LG Chem

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Innovent Biologics

New programs 4

  • IBI3043phase 1 · first study · Oct 22
  • IBI3034phase 1 · first study · Oct 8 · Glomerulonephritis, IGA
  • telitaciceptphase 2 · first study · Sep 13 · Lupus Erythematosus, Systemic
  • IBI3046phase 1 · first study · Sep 3 · Obesity

Reached a new phase 2

  • IBI3011phase 2 · Sep 14 · Gout
  • IBI355phase 2 · Sep 13 · Sjogren's Syndrome

Study stopped 1

  • IBI356phase 2 · terminated Oct 27 · none of its studies left running“Sponsor Decision” · NCT07330934

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionLG ChemInnovent Biologics
Obesityboth · compare here

LG Chem in Obesity: 1 program

  1. Metforminphase 3

Their studies: LG Chem’s studies of Obesity in search

Innovent Biologics in Obesity: 4 programs

  1. mazdutidephase 3
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. IBI3046phase 1

Their studies: Innovent Biologics’ studies of Obesity in search

Diabetes Mellitus, Type 2both · compare here

LG Chem in Diabetes Mellitus, Type 2: 3 programs

  1. Metforminphase 3
  2. dapagliflozinphase 3
  3. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Diabetes Mellitus, Type 2 in search

Innovent Biologics in Diabetes Mellitus, Type 2: 1 program

  1. mazdutidephase 3

Their studies: Innovent Biologics’ studies of Diabetes Mellitus, Type 2 in search

Renal Insufficiencyboth · compare here

LG Chem in Renal Insufficiency: 1 program

  1. gemigliptinapproved, new study

Their studies: LG Chem’s studies of Renal Insufficiency in search

Innovent Biologics in Renal Insufficiency: 3 programs

  1. gimeracilphase 2
  2. Oxonic Acidphase 2
  3. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Renal Insufficiency in search

Breast Neoplasmsboth · compare here

LG Chem in Breast Neoplasms: 1 program

  1. Leuprolideapproved, new study

Their studies: LG Chem’s studies of Breast Neoplasms in search

Innovent Biologics in Breast Neoplasms: 1 program

  1. Anti-HER2 Antibody-drug Conjugate IBI354phase 3

Their studies: Innovent Biologics’ studies of Breast Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: LG Chem 5 of 10 · Innovent Biologics 16 of 40 programs (20 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.